BioSpace News Archive

Longhorn Vaccines and Diagnostics LLC, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, announced that Zoe Silver has joined the company as Senior Vice President of Genomics & Diagnostics.

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology drugs, announced today that the management team will participate in the H.C. Wainwright 24th Annual Global Investment Conference that will be held September 12th – 14th.

Checkpoint Therapeutics, Inc. announced that James Oliviero, President and Chief Executive Officer, will participate in two upcoming investor conferences.

New detailed results from Eli Lilly and Company’s (NYSE: LLY) Phase 3 monotherapy studies in atopic dermatitis (AD) showed investigational lebrikizumab provided robust and durable improvements in skin clearance and itch for patients who achieved a clinical response* at Week 16 through one year of treatment.

Biofidelity, a revolutionary genomic technology company dedicated to unleashing the potential of genomics to transform human health and the world we live in, announced the issuance of several new patents in the US, Europe, and China.

Amgen (NASDAQ:AMGN) today announced results from two significant Phase 3 clinical studies of oral Otezla® (apremilast), demonstrating efficacy in pediatric patients with moderate to severe plaque psoriasis and in adults with moderate to severe genital psoriasis, at the 31st European Academy of Dermatology and Venereology (EADV) Congress, taking place in Milan, Italy, Sept. 7-10, 2022.

Calidi Biotherapeutics, Inc., a clinical-stage biotechnology company that is pioneering allogeneic cell-based platforms to revolutionize oncolytic virus therapies, announced that senior management will present a company overview at two upcoming investor conferences.

Lunaphore and Nucleai, a leader in AI-powered spatial biology transforming precision medicine by unlocking the power of pathology data, today announced a collaboration to accelerate the discovery of novel biomarkers and drug targets using the latest spatial imaging and machine learning technologies.

Quotient Limited, a commercial-stage diagnostics company, headquartered in Eysins, Switzerland, announced it was selected by the World Economic Forum to join their New Champions Community.

Valneva SE and VBI Vaccines Inc. announced a partnership in select European markets for the marketing and distribution of PreHevbri® [Hepatitis B vaccine ], the only 3-antigen hepatitis B vaccine approved in Europe.